| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Signal Pharmaceuticals, Inc. |
| 5555 Oberlin Drive, San Diego, CA 92121 * (619) 558-7500 |
| Signal is an integrated target and drug discovery company focused on identifying new classes of small molecule drugs that regulate genes and the production of disease-causing proteins. |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 439-3626 |
| BancAmerica Robertson Stephens | Co-manager | (415) 989-8500 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| NASNTL: | SGNL | Service: | SIC 8731 | |
| Type of Shares: | Common Shares | Filing Date: | 5/15/98 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,500,000 | Expenses: | $600,000 | |
| Secondary Shares: | 0 | Post-IPO Shares: | 9,433,929 | |
| Employees: | 82 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Brobeck, Phleger & Harrison |
| Registrar/Transfer Agent: | ChaseMellon Shareholder Services, L.L.C. |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 3/31/98 | 3/31/97 | 3/31/98 | ||
| Revenue: | $7.58 | $4.64 | $1.55 | Assets: | $24.75 |
| Net Income: | -$5.74 | $0.34 | -$1.67 | Curr Assets: | $21.27 |
| EPS: | -$1.20 | $0.05 | Liabilities: | $9.11 | |
| Prior EPS: | Curr Liab: | $6.64 | |||
| Cash Flow/Oper: | -$2.34 | $1.07 | -$2.02 | Equity: | $15.65 |
| Cash Flow/Fin: | $17.98 | -$0.26 | -$0.10 | Cash: | $20.67 |
| Cash Flow/Inv: | -$12.37 | $3.37 | -$0.15 | Working Cap: | $14.64 |
| Competition |
| Competition among pharmaceutical and biopharmaceutical companies to identify drug targets and drug candidates for development is intense and is expected to increase. In the pharmaceutical industry, the Company competes with the research and development departments of pharmaceutical and biopharmaceutical companies and other commercial enterprises, as well as numerous academic and research institutions and governmental agencies. In addition, the pharmaceutical and biopharmaceutical industries are subject to rapid and substantial technological change. Pharmaceutical and biopharmaceutical companies and others are conducting research in various areas which overlap with the Company's technology platform, either on their own or in collaboration with others. There can be no assurance that pharmaceutical and biopharmaceutical companies which compete with the Company in specific areas will not merge or enter into collaborations or joint ventures or other alliances with one or more other such companies or academic and research institutions and become substantial competitors or that the Company's collaborators will not initiate or expand their own internal target and drug discovery and development efforts. |
| Business Plan |
| The Company's goal is to be a leader in the discovery of small molecule drugs that target gene regulating pathways fundamental to disease processes. To accomplish this goal, the Company pursues the following technology and business strategies: (I) Integrate Advanced Target and Drug Discovery Technologies, (ii) Leverage Targets Across Multiple Diseases, (iii) Build Partner-Funded Business, (iv) Retain Significant Product Commercialization Rights. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, including internal discovery programs and joint research and development with corporate and academic collaborators, the acquisition of research and development technologies, compound screening libraries and product rights, capital investments and working capital and general corporate purposes. |